RecruitingPhase 3NCT05400317

A Study to Evaluate the Efficacy and Safety of AD-218

A Randomized, Double-blinded, Active-controlled, Multicenter Phase 3 Clinical Trial and Open-label, Extension Study to Evaluate the Efficacy and Safety of AD-218 in Patients with Mixed Dyslipidemia

Sponsor

Addpharma Inc.

Enrollment

520 participants

Start Date

Jul 27, 2022

Study Type

INTERVENTIONAL

Conditions

mixed dyslipidemia

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-218

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AD-218 and a drug called AD-218A for people with mixed dyslipidemia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.